The ROR family of receptor tyrosine kinases, ROR1 and ROR2, is known to play an important role during skeletal muscle regeneration. ROR1 has a critical role in regulating satellite cell (SC) proliferation during muscle regeneration, and proinflammatory cytokines such as TNF-a and IL-1b can induce expression of ROR1 in myogenic cells via NF-jB activation. While searching for ROR1-interacting proteins in myogenic cells, we identified MuSK as a ROR1-binding protein. MuSK interacts with and phosphorylates ROR1 at the cytoplasmic proline-rich domain. ROR1 also interacts with the MuSK activator Dok-7 independently of MuSK interaction. Collectively, our results identified ROR1 as a new interacting partner for MuSK and Dok-7, which may have an important role in myogenic cell signaling.
The receptor tyrosine kinase-like orphan receptor (ROR) family is a part of the neurotrophic tyrosine kinase superfamily (NTRK) along with the muscle-specific kinase (MuSK) and Neuro-specific receptor kinase (Nrk) family, Discoidin domain receptors (Ddr) family, and tropomyosin-related kinase (Trk) family [1] . ROR proteins mediate an array of cellular functions such as cell polarity, proliferation, migration, and differentiation through the activation of noncanonical Wnt signaling [1, 2] . Although RORs were initially identified as "orphan" receptors since their associated ligands and signaling pathways were unknown [3] , recent studies in multiple species have shown that RORs are Wnt receptors capable of binding Wnt ligands to modulate the transcription of their target genes [1, 4] . ROR proteins are type-I transmembrane receptors predominantly located at the plasma membrane. Mammalian RORs have a domain architecture composed of an extracellular immunoglobulin (Ig) domain, a Cys-rich domain (CRD) also called a Frizzled domain, and a Kringle (KR) domain; this is followed by a transmembrane helix and an intracellular domain consisting of a tyrosine kinase-like domain and two Ser/Thr-rich domains flanking a Pro-rich domain. The extracellular CRD of ROR is similar to the Wnt binding domain that is found in Frizzled receptors, and serves as a binding site for Wnt ligands. ROR tyrosine kinase-like domain lacks several conserved amino acids that are normally found in the canonical motifs of active kinases and are required for proper catalytic activity, therefore RORs are known as catalytically inactive pseudokinases [5, 6] . ROR proteins are evolutionarily conserved and ROR orthologs have been identified in species such as fruit flies (Drosophila melanogaster), roundworms (Caenorhabditis elegans), zebrafish (Danio rerio), chickens (Gallus gallus), frogs (Xenopus laevis) and mice (Mus musculus), underlining their important biological functions as confirmed by gene knockout studies [7] . mROR1 À/À mice have a reduced life expectancy due to postnatal growth retardation, whereas mROR2 À/À mice die at birth due to severe skeletal and heart abnormalities [8] [9] [10] . mRor1 and mRor2 are functionally redundant during cardiac and skeletal development, with mRor2 being able to compensate for the functions of mRor1 in mRor1 À/À mice [11] .
As a member of the same NTRK superfamily, MuSK plays an essential role in the neuromuscular junction (NMJ) formation, where it is critically involved in organization of acetylcholine receptors (AChRs) within the agrin receptor complex in the postsynaptic apparatus [12, 13] . Consequently, MuSK knockout mice do not form neuromuscular synapses, lack AChRs clustering, and die soon after birth [14] . MuSK receptor contains an extracellular domain consisting of three Ig-like domains and a Frizzled-like CRD, whereas the intracellular domain includes a juxtamembrane region with a key NPXY motif (where X stands for any amino acid) for tyrosine phosphorylation followed by a tyrosine kinase domain, and a short cytoplasmic tail [13] . As in the case of CRD of RORs, MuSK CRD domain is able to bind several Wnt ligands that can modulate MuSK activation and AChR clustering in muscle cells [15] [16] [17] . Activation of MuSK at the NMJ formation involves its interaction with three other muscle proteins: low-density lipoprotein receptor-related protein-4 (LRP4) which acts as transmembrane ligand activator (in cis) for MuSK, downstream of tyrosine kinase-7 (Dok-7) which serves as cytoplasmic activator of MuSK, and rapsyn which binds directly to and regulates AChR clustering [13] .
Muscle-specific kinase is predominantly expressed in skeletal muscle but is also found in excitatory neurons from the mammalian central nervous system (CNS), whereas both ROR1 and ROR2 and their ligand Wnt5a were shown to play roles in regulating neurite extension, synapse formation, and synaptic transmission of hippocampal neurons [18, 19] . Recently, it has been shown that expression of ROR1 and ROR2 was induced in skeletal muscle and satellite cells (SCs) by inflammatory cytokines such as TNF-a and IL-1b, and ROR1 plays an important role in regulating proliferation of SCs during skeletal muscle regeneration [20] .
In this study, we investigated the biochemical and functional interaction between ROR1 and MuSK in vitro and in myogenic cells. Our results indicate that ROR1 is able to bind to MuSK and Dok-7 and is a substrate for MuSK phosphorylation, which can confirm its role in myogenic differentiation and muscle cell regeneration.
Materials and methods

DNA plasmids
Human ROR1, ROR2, LRP4 and rat MuSK were cloned into the pCINeo expression vector (Promega, Madison, WI, USA) with an HA, myc, flag or His tag as indicated. MuSK (rat) and Dok-7 plasmids were a kind gift from Dr. Hubbard's lab (NYU) [21] . Mutations K506A in ROR1 and K608A in MuSK were done using QuickChange II Site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA) according to manufacturer's instructions. All constructs were sequenced to verify the correct DNA sequence of the insert.
Cell culture and transfections
293T, Cos-7, and C2C12 cells were cultured in DMEM (Lonza, Basel, Switzerland) supplemented with 10% FBS, 2 mM L-glutamine and 1% penicillin-streptomycin and incubated at 37°C and 5% CO 2 . For differentiation of myogenic C2C12 cell line, cells were allowed to reach 100% confluence and then switched to differentiation media containing 2% horse serum. Transfections were done using TurboFect (Thermo Fisher Scientific, Waltham, MA, USA) or FuGENE HD (Promega) reagents according to manufacturer's instructions.
Immunoprecipitations and western blotting
Transfected cells were lysed in buffer containing 30 mM triethanolamine, pH 7.5; 1% NP-40; 50 mM NaF; 2 mM Na 3 VO 4 ; 1 mM sodium tetrathionate, pH 7; 5 mM EDTA; 5 mM EGTA, pH 7.5; 1 mM N-ethylmaleimide and 50 mM NaCl [21] supplemented with protease and phosphatase inhibitor cocktails (Biomake, Houston, TX, USA). Immunoprecipitation was done by incubating the lysates with primary antibodies O/N at 4°C, followed by the addition of protein sepharose beads (1 h at 4°C) and subsequent bead washes. Beads were resuspended in 2x Laemmli buffer containing reducing agents and boiled prior to loading onto SDS/PAGE gels. Lysates and/or immunoprecipitations were separated on SDS/PAGE and transferred to nitrocellulose membrane. 
Biotinylation assay
After 24 h, transfected Cos-7 cells were washed twice with 1 mM CaCl 2 and 1 mM MgCl 2 in PBS and incubated for 30 min at 4°C with occasional gentle shaking in biotin solution (0.5 mgÁmL À1 sulfo-NHS-SS biotin, 1 mM CaCl 2 , 1 mM MgCl 2 in PBS) followed by 3x 10 min at 4°C washes with quenching solution (100 mM glycine, 1 mM CaCl 2 , 1 mM MgCl 2 in PBS, pH 7.4) and final wash with 1 mM CaCl 2 and 1 mM MgCl 2 in PBS. Next, cells were lysed in lysis buffer (10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.5% NP-40; 1 mM CaCl 2 ; 1 mM MgCl 2 + protease inhibitors) and incubated 20 min at 4°C with gentle shaking followed by centrifugation. Supernatants were transferred to new tubes and input samples were taken. For the rest of the lysates, the volume was increased with dilution buffer (10 mM Tris-HCl, pH 7.5; 150 mM NaCl + protease inhibitors) to lower the detergent concentration to less than 0.2%. Streptavidin beads were added for 2 h, followed by washes, SDS/PAGE gel and western blotting.
ROR1 expression analysis
In the FANTOM project, cap analysis gene expression (CAGE) sequencing of cDNA has been performed in 1839 human samples from 875 different primary cells, tissues, and cell lines [23] . Absolute expression values of ROR1 are presented as tags per million (TPM) and expression data was extracted for cells and tissues of interest and those where ROR1 expression was highest.
Replicates were pooled and plotted using the Matplotlib library for Python [24] , and custom scripts designed for this analysis.
Results
ROR1 is a MuSK substrate and becomes phosphorylated by activated MuSK at the cytoplasmic proline-rich domain
Given that both RORs and MuSK share common structural similarities (Fig. 1A ,B), we investigated whether RORs and MuSK could interact in vitro and whether activation of MuSK by the cytoplasmic Dok-7 protein has any impact on this interaction. For this purpose, Cos-7 cells were transfected with expression plasmids encoding for ROR1, MuSK, and Dok-7, and 48 h after transfection, cells were lysed and proteins were immunoprecipitated followed by western blotting as indicated in Fig. 2A (and Fig. S1A ). As previously shown, coexpression of MuSK and Dok-7 resulted in robust phosphorylation of both proteins, since Dok-7 binding to Tyr553 in the MuSK juxtamembrane domain leads to full activation of MuSK [21] . Interestingly, we observed a robust phosphorylation of ROR1 when coexpressed with MuSK and Dok-7, as well as phosphorylation of MuSK and Dok-7, although Dok-7 phosphorylation was markedly decreased compared to the sample with MuSK and Dok-7 cotransfection only. Since ROR1 was phosphorylated in the presence of activated MuSK, we next investigated whether ROR1 is able to interact with MuSK or Dok-7. ROR1 was cotransfected with either MuSK or Dok-7 or both, and ROR1 was immunoprecipitated using anti-ROR1-specific antibodies (binding to N-or C terminus of ROR1) followed by western blotting for MuSK or Dok-7. As shown in Fig. 2B , ROR1 immunoprecipitation using either N-or C terminusspecific antibodies could pull-down MuSK or Dok-7 whether coexpressed individually or as ROR1-MuSKDok-7 complex. Of note, phosphorylation of ROR1 was detected only in the presence of MuSK and Dok-7 coexpression. We also checked whether ROR2 is phosphorylated in the presence of MuSK and Dok-7 and the results showed that ROR2 phosphorylation was minimal (Fig. S1B) . Next, we assessed whether the kinase activity of MuSK is required for MuSK-ROR1 interaction and ROR1 phosphorylation. Consecutively, we mutated the invariant Lys in b3 strand to create a kinase-dead mutant of MuSK (K608A). Cos-7 cells were cotransfected with ROR1 together with Dok-7 and either MuSK WT or MuSK K608A and the lysates were subjected to ROR1, MuSK, and Dok-7 immunoprecipitations followed by western blot analysis with specific antibodies (Fig. 2C) . Phosphorylation of ROR1 was detected only in the presence of MuSK WT but not MuSK K608A, suggesting that MuSK kinase activity is required for ROR1 phosphorylation. Moreover, ROR1 was able to coimmunoprecipitate with MuSK K608A (even more than with MuSK WT), indicating that the kinase-dead mutation of MuSK does not impair MuSK-ROR1 interaction. Interestingly, analysis of ROR1 levels (total and phospho-protein levels) from MuSK immunoprecipitated samples revealed that it is mostly the unphosphorylated ROR1 that associates with MuSK (Fig. S1C ), indicating that their interaction is phosphorylation independent. Dok-7 phosphorylation was also detected only in the presence of MuSK WT cotransfection (Fig. 2C) , indicating, as previously demonstrated, that MuSK kinase activity is required for Dok-7 phosphorylation [21] . Since full-length ROR1 protein was previously suggested to possess catalytic activity and phosphorylate Her3 [25] and this function was abolished by K506 mutation, we investigated whether K506A mutation in ROR1 would affect ROR1 phosphorylation by activated MuSK. As shown in Fig. 2D , ROR1 WT and ROR1 K506A were equally phosphorylated by activated MuSK and phosphorylation of MuSK and Dok-7 was not affected by ROR1 K506A coexpression, suggesting that K506A mutation in ROR1 has no effect on ROR1-MuSK-Dok-7 interaction.
Furthermore, we wanted to identify the cytoplasmic domain of ROR1 that is phosphorylated by activated MuSK. For this purpose, 293T cells were cotransfected with several ROR1 truncation plasmids (as described in Fig. 3A) together with MuSK and Dok-7, and ROR1 was immunoprecipitated followed by anti-pTyr western blotting. As shown in Fig. 2E , ROR1 WT, ROR1 (1-876), and ROR1 (1-851) truncations were robustly phosphorylated by activated MuSK, whereas ROR1 (1-782) and ROR1 (1-752) were not. Therefore, ROR1 phosphorylation domain by the activated MuSK is localized or mediated by its Pro-rich domain. It remains to be determined the exact residue(s) of MuSK-mediated ROR1 phosphorylation and whether these residues are localized only in the Pro-rich domain or in other domains as previously shown with MET1-mediated phosphorylation of ROR1 [26] .
ROR1 interacts independently with MuSK and Dok-7
Since ROR1 is phosphorylated by activated MuSK, we wanted to determine whether ROR1 could interact in vitro with MuSK or Dok-7. For this purpose, we created several truncations of ROR1 (Fig. 3A) and tested their interaction with either MuSK or Dok-7 in 293T cells in cotransfection experiments. As shown in Fig. 3B , ROR1 WT as well as ROR1 truncations with deleted C-terminus Ser/Thr and/or Pro-rich domains were able to interact with MuSK or Dok-7 (Fig. 3C) , suggesting that ROR1 can independently bind in vitro to either of these proteins.
On the other hand, interaction of ROR1 intracellular cytoplasmic domains (ROR1 453-937 and subsequent C terminus deletions) with either MuSK or Dok-7 was significantly diminished and the phosphorylation of these proteins by the activated MuSK was not observed (Fig. 3D,E, Fig. S1D ). Deletion of N terminus ROR1 domains including the transmembrane (TM) domain would imply that these ROR1 truncations are not localized at the plasma membrane but in the cytosol, suggesting that ROR1-MuSK-Dok-7 interaction takes place at the plasma membrane, as expected. Receptor biotinylation pull-down using ROR1 WT and different C terminus truncations and Dok-7 coexpression revealed stronger Dok-7 pulldown in samples expressing ROR1, indicating that ROR1-Dok-7 interaction takes place at the plasma membrane (Fig. S1E) .
Deletion of ROR1 CRD or Kringle domain did not impair its interaction with MuSK (data not shown), indicating that MuSK-ROR1 interaction is not depended on these extracellular ROR1 domains. The remaining pseudokinase domain of ROR1 could be the responsible domain for MuSK or Dok-7 interaction, however, deletion of pseudokinase domain severely affected ROR1 protein stability and expression, affecting the validation of this interaction.
ROR1 interacts with LRP4
Low-density lipoprotein receptor-related protein 4 interacts with MuSK and is critical for agrin-induced AChR clustering and muscle cell prepatterning [27] [28] [29] . Thus, we examined whether ROR1 could also interact with LRP4 in vitro and for this purpose, Cos-7 cells were cotransfected with LRP4, ROR1, and MuSK, and protein complexes were detected by immunoprecipitation and western blotting. As shown in Fig. 3F , LRP4-MuSK, LRP4-ROR1, and LRP4-MuSK-ROR1 complexes were readily detected after but did not influence ROR1 phosphorylation in LRP4-ROR1 or LRP4-MuSK-ROR1 samples (data not shown).
ROR1 is endogenously expressed in differentiated C2C12 myotubes and in myogenic cells
Next, we validated ROR1-MuSK interaction using mouse myogenic cell line C2C12 that has been used as an in vitro experimental model for myogenic differentiation. Differentiation of C2C12 myoblasts into myotubes takes place under low serum condition within 2-6 days when these cells start to express Dok-7 and MuSK, as previously demonstrated [30] .
In agreement with this, we cultured C2C12 myotubes and started the differentiation process while monitoring MuSK, Dok-7, and ROR1 endogenous expression. As shown in Fig. 4A , qPCR analysis revealed an increase in mRNA levels for MuSK and ROR1 after 4 days of differentiation. More importantly, we detected ROR1 protein expression in differentiated myotubes (highest expression at day 6), along with increased levels of Dok-7 and MuSK (Fig. 4B ). ROR1-MuSK complex was readily detected by immunoprecipitation of differentiated C2C12 myotubes (day 6), indicating that ROR1 and MuSK can interact in vivo. Analysis of ROR1 expression in the FANTOM dataset in 15 tissues and cell types is presented in Fig. 4C . We observe significant expression in muscle and fat related cell types, as well as in previously observed tissues of pancreas and lung [22, 31] . The highest expression, by median value, was observed in preadipocytes, heart, and myocytes. We noted less than 1 TPM expression for ROR1 in liver (no expression), as has also been previously observed [22] .
Discussion
In this study, we demonstrate for the first time that ROR1 pseudokinase interacts with and becomes phosphorylated at the cytoplasmic Pro-rich domain by activated MuSK. Moreover, we provide evidence that ROR1 interacts with Dok-7 as well as LRP4, two other proteins with key roles in muscle cell signaling.
Receptor tyrosine kinase-like orphan receptor 1 expression in postpartum healthy tissue is regarded as relatively weak compared with high levels during embryonic stages [11] . The development of a more performant anti-ROR1 monoclonal antibody (clone 6D4) helped to detect ROR1 expression is several healthy adult tissues such as parathyroid, pancreatic islets, and several regions of the human gut, and high ROR1 levels were observed in the stomach antrum and gastric body [22] . Moreover, Sanchez-Solana et al. [31] , have shown that ROR1 is expressed in preadipose cells where it interacts with resistin to modulate adipogenesis and glucose metabolism. Diaz-Horta et al. [32] , have demonstrated that ROR1 is expressed in the inner ear during development at embryonic and postnatal stages, and ROR1 mRNA have been detected in several postnatal organs such as brain, lung, kidney, and liver. Our FANTOM analysis identified ROR1 expression in several myogenic and musclerelated tissues that was similar to adipose or pancreatic tissues as previously suggested [22] . Therefore, it is likely possible that ROR1 is expressed in other healthy adult tissues but at low levels. However, its functional roles should not be underestimated by its modest expression. Interestingly, MuSK shows a similar expression pattern as ROR1, relatively low levels are found in adult brain and muscle compared with higher levels in both tissues during development, but this does not underscore its important functional roles in several adult tissues, including muscle and brain [19, [33] [34] [35] . Several studies have documented the expression of ROR family of proteins in the developing nervous system in both, invertebrates and vertebrates [18] , and ROR1, ROR2, and their ligand Wnt5a have been implicated in regulating synaptic plasticity. A similar role has been attributed to MuSK, suggesting that RORs and MuSK could be common modulators of synaptic plasticity in hippocampal neurons [19] . The presence of a common Wnt ligand-binding CRD domain in RORs and MuSK indicates that these receptors are able to bind Wnt ligands. Wnt5a has been confirmed as the ligand for ROR1 and ROR2 [4] , whereas both MuSK and LRP4 were shown to bind several Wnt ligands [17] that can activate the canonical or noncanonical Wnt pathways, although common Wnt ligands of ROR and MuSK are yet to be identified. Interestingly, in zebrafish muscle-derived Wnts act as a ligand for MuSK activation through the interaction with its CRD domain, whereas in mice this role is replaced by LRP4 that serves as cis-acting ligand for MuSK [36] . Moreover, mammalian MuSK has lost its Kringle domain that is still found in MuSK from all other vertebrates and in mammalian RORs, although the functional role of this domain is still elusive. Apart from MuSK, ROR1 was able to bind to LRP4 and Dok-7, suggesting that ROR1-MuSK interaction could be a part of a more complex receptor module that regulates signaling in muscle or neuronal cells. Thus, we can speculate that RORs and MuSK evolved from ancestral invertebrate kinases by reshaping their domain architecture and/or interacting partners to support their specialized functions in higher organisms.
Interestingly, recent studies have shown that ROR1 plays a critical role in regulating proliferation of satellite cells (SCs) during skeletal muscle regeneration [20] . ROR1 and ROR2 mRNA and protein expression was detected in skeletal muscle following cardiotoxininduced injury, whereas ROR1 expression was constitutively detected in SCs cells. Activation of NF-jB p65 by inflammatory cytokines such as TNF-a or IL1-b induced ROR1 expression in C2C12 myogenic cells, suggesting that ROR1 plays a role in regulating inflammatory responses in these cells. Moreover, ROR1 was required for proliferative responses of C2C12 cells, since suppression of ROR1 expression resulted in significant inhibition of TNF-a-induced proliferation of C2C12 cells. Using the same myogenic cell line, we detected expression of ROR1 in differentiated C2C12 myotubes, along with expression of MuSK and Dok-7 as previously shown [30] , and ROR1 could interact with MuSK in these cells. At present, the signaling pathway downstream of ROR1 in myogenic cells and whether NF-jB activation could play a role in modulation of ROR1 interactions with MuSK, Dok-7, or LRP4 remain to be investigated. Muscle-specific kinase activation and subsequent engagement of signaling events at the NMJ is a complex mechanism yet to be fully understood. Phosphorylation of Y553 in the juxtamembrane region of MuSK serves as a docking site for Dok-7. Binding of Dok-7 to MuSK results in full MuSK activation and subsequent Dok-7 phosphorylation, since MuSK Y553F is completely devoid of phosphorylation, even in the presence of Dok-7. We observed that it is mainly the unphosphorylated form of ROR1 that binds to MuSK, as judged by Co-IP experiments from ROR1-MuSK-Dok-7-transfected lysates. Dok-7-ROR1 interaction was quite weak in samples cotransfected with ROR1 and MuSK, suggesting that ROR1 binds more to MuSK than to Dok-7 when all three proteins are coexpressed. MuSK kinase activity was required for ROR1 phosphorylation, but did not abolish its interaction with ROR1. On the other hand, the unphosphorylated MuSK K608A mutant could pull-down more ROR1 protein than MuSK WT. We show that ROR1 could interact with both MuSK and Dok-7, however, it is unclear whether ROR1 is phosphorylated by activated MuSK or by fully phosphorylated Dok-7, and this warrants further investigation.
The Pro-rich domain of ROR1 has been shown to play important roles in ROR1 signaling. MET1 interacts with and phosphorylates ROR1 at the Pro-rich domain, although similar to ROR1-MuSK interaction, C terminus truncations of ROR1 including Pro-rich domain deletion were still able to bind MET1 [26] . Interestingly, mutations of all Tyr residues in ROR1 Pro-rich domain did not abolish MET1-mediated phosphorylation since SRC recruitment and binding to this domain could induce additional phosphorylation events in ROR1 pseudokinase domain. Thus, we could speculate that binding of SRC to ROR1 Pro-rich domain could play a role in MuSK-mediated ROR1 phosphorylation, however, MuSK K608A kinase-dead mutation was able to completely abolish ROR1 phosphorylation, indicating that the kinase activity of MuSK is mainly responsible for this phosphorylation. More recently, in a leukemia model, ROR1 Pro-rich domain was shown to bind HS1 (Hematopoieticlineage-cell-Specific protein 1) to enhance chemokinemediated cell migration, whereas in lung adenocarcinoma it binds to ASK1 (apoptosis signal-regulating kinase 1) to repress proapoptotic signaling [37] . Therefore, ROR1 Pro-rich domain appears as a docking and/or phosphorylation site for several interacting proteins and signaling modulators downstream of ROR1 not only in cancer cells but also in nonmalignant cells as in the case of MuSK-mediated phosphorylation in myogenic cells.
Our findings identified ROR1 as a new interacting partner for MuSK, Dok-7, and LRP4. ROR1 interaction with multiple proteins expressed in myogenic cells can be used to ascertain its roles in muscle regeneration and muscular disorders as previously suggested [20] , while providing clues about signaling pathways employed by ROR1 in these cells.
